NASDAQ
No price data available for this timeframe.
Celldex Therapeutics, Inc. (CLDX) has a price/fcf ratio of -8.45x as of Monday, May 25, 2026. This represents a 54.46% increase compared to its 12-month average of -18.56x. The price-to-free-cash-flow ratio measures a stock's price relative to its free cash flow per share, reflecting how efficiently a company generates cash.